Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Hematologic Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04606433
What this trial is testing

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Who this might be right for
Non Hodgkin LymphomaAcute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd. 47
Early research (Phase 1)Study completedNCT02096289
What this trial is testing

Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Ontario Clinical Oncology Group (OCOG) 13
Early research (Phase 1)Active Not RecruitingNCT03190278
What this trial is testing

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia
Cellectis S.A. 29
Not applicableStudy completedNCT00919425
What this trial is testing

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
SWOG Cancer Research Network 1,294
Testing effectiveness (Phase 2)Ended earlyNCT05886491
What this trial is testing

GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Leukemia
Takeda 16
Testing effectiveness (Phase 2)Study completedNCT01702155
What this trial is testing

Phase I/II Study of DFP-10917 in Patients With Acute Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic Leukemia
Delta-Fly Pharma, Inc. 69
Early research (Phase 1)Study completedNCT03181126
What this trial is testing

Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Lymphoblastic Lymphoma
AbbVie 69
Early research (Phase 1)Ended earlyNCT02978235
What this trial is testing

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Who this might be right for
Multiple MyelomaNonHodgkin Lymphoma
Taiho Oncology, Inc. 11
Testing effectiveness (Phase 2)Ended earlyNCT05117008
What this trial is testing

Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaRelapse Multiple Myeloma
Medical College of Wisconsin 1
Early research (Phase 1)Ended earlyNCT02137889
What this trial is testing

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Who this might be right for
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Novartis Pharmaceuticals 3
Not applicableStudy completedNCT03098589
What this trial is testing

Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Who this might be right for
Lymphoma
Celgene 1,149
Early research (Phase 1)Study completedNCT03733717
What this trial is testing

Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Sanofi 25
Testing effectiveness (Phase 2)Ended earlyNCT03201250
What this trial is testing

Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaRelapsed/Refractory Multiple Myeloma
University of Nebraska 11
Testing effectiveness (Phase 2)WithdrawnNCT04354025
What this trial is testing

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Who this might be right for
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Washington University School of Medicine
Testing effectiveness (Phase 2)Ended earlyNCT03071276
What this trial is testing

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
St. Jude Children's Research Hospital 37
Testing effectiveness (Phase 2)UnknownNCT01886976
What this trial is testing

Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138

Who this might be right for
Multiple Myeloma
Chinese PLA General Hospital 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03162536
What this trial is testing

Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

Who this might be right for
Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 190
Early research (Phase 1)UnknownNCT03674463
What this trial is testing

LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Second Affiliated Hospital of Xi'an Jiaotong University 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT03467867
What this trial is testing

Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Who this might be right for
Chronic Lymphocytic Leukemia
Georgetown University 25
Early research (Phase 1)Study completedNCT00004009
What this trial is testing

R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia

Who this might be right for
Leukemia
University of Maryland, Baltimore
Next Page